A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide
Completed · Phase 4
Conditions studied: Osteoporosis, Postmenopausal
In brief
The purpose of this study is to use imaging technologies to demonstrate the effects of teriparatide on bone structure following 18 to 24 months of therapy in postmenopausal women with osteoporosis.
Key facts
- Study ID
- NCT00557310
- Run by
- Eli Lilly and Company
- People needed
- 35
- Starts
- 2007-11-01
- Expected to finish
- 2011-05-01
- Last updated by the study team
- 2011-11-11
Who can join
Age: 45 and older, up to 85. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- postmenopausal (after the "change of life") women with osteoporosis
- between the ages of 45-85
- have low bone mass as determined by a bone density test
- have at least one prior atraumatic vertebral or nonvertebral fracture(with a T-score of -2.0 or lower at the lumbar spine, total hip, or femoral neck) or, no prior fracture (with a T-score of -3.0 or lower at these same sites)
- could have taken up to 5 years total of certain oral osteoporosis medications such as alendronate, risedronate, or ibandronate
You may not qualify if…
- have conditions that would affect the bone in the region of the wrist or have had a previous fracture of either wrist which might affect results of study
- have a metal implant or have had a hip replacement in either hip which might affect results of study
- have an increased risk of osteosarcoma; includes Paget's disease of bone, a previous bone tumor, or x-ray treatment to the skeleton
- currently have active or suspected diseases that affect the bone, other than osteoporosis
- have abnormal levels of calcium, parathyroid hormone in blood, or other laboratory values
Where it is running
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Tucson, Arizona, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Lakewood, Colorado, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Omaha, Nebraska, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Albuquerque, New Mexico, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Pittsburgh, Pennsylvania, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Vancouver, British Columbia, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.